Nano Miscellaneous
Market Cap
₹4 ₹4.00 Cr.
P/E
0.00
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

  • EVOQ Remedies
  • Dipna Pharmachem
  • Deccan Health Care

FAQs on EVOQ Remedies Ltd. Shareprice

EVOQ Remedies has given lower returns compared to its competitors.
EVOQ Remedies has grown at ~-47.36% over the last 4yrs while peers have grown at a median rate of -13.35%

EVOQ Remedies is not expensive.
Latest PE of EVOQ Remedies is 0, while 3 year average PE is 46.49.
Also latest EV/EBITDA of EVOQ Remedies is 0 while 3yr average is 4.79.

Growth Table

  • EVOQ Remedies Ltd.
  • Dipna Pharmachem
  • Deccan Health Care

Balance Sheet

  • EVOQ Remedies Ltd.
  • Dipna Pharmachem
  • Deccan Health Care

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • EVOQ Remedies Ltd.
  • Dipna Pharmachem
  • Deccan Health Care

Cash Flow

  • EVOQ Remedies Ltd.
  • Dipna Pharmachem
  • Deccan Health Care

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • EVOQ Remedies Ltd.
  • Dipna Pharmachem
  • Deccan Health Care

Quarterly Results

  • EVOQ Remedies Ltd.
  • Dipna Pharmachem
  • Deccan Health Care

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on EVOQ Remedies Ltd. Financials

Balance sheet of EVOQ Remedies is moderately strong.

Yes, The net debt of EVOQ Remedies is increasing.
Latest net debt of EVOQ Remedies is ₹0.07 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹0.23 Crs.

No, profit is decreasing.
The profit of EVOQ Remedies is ₹0.09 Crs for Mar 2025, ₹0.45 Crs for Mar 2024 and ₹1.62 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
EVOQ Remedies latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Accounts Receivable, Short Term Loans & Advances

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech